Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib for BTK inhibitor–intolerant indolent non-Hodgkin lymphoma (iNHL)
ChiCTR2400080207Phase 2Recruiting
- Sponsor
- HuZhou Central Hosptial
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL) and 2 more, sponsored by HuZhou Central Hosptial. Primary endpoint: Adverse events. Started Jan 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)indolent lymphoma
Beyond the preview
Go deeper on ChiCTR2400080207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080207.